Website value calculator & SEO Checker => obroncology.com
SEO report with information and free domain appraisal for obroncology.com. It is a domain hosted in . Its server is hosted on IP 18.66.196.2. The domain is ranked at the number 2995269 as a world ranking of web pages. According to estimated data we have access to potential gains of this site are 18 dollars per month. In annual terms, the domain obroncology.com could be earning more than 214 dollars. If someone wanted to buy the domain a good selling price would be 2135 dollars.
These data are estimated and can not be taken as 100 % real. Only give an estimate of profits depending on the subject and the traffic generated by obroncology.com . The estimated number of unique visitors accessing obroncology.com is 155. Thus the total number of people who visit this page per month would be 4664 people.
Domain Authority
SEO Score
☰ Report Resume
- SEO score
- Speed
- Page Load Time
- Current Ip of the domain: 18.66.196.2
- Charset of page: UTF-8
- Total Keywords: 826
- Total Links: Anchor textTypeLinkNewslettersfollow/newsletterfollow/Cancer Typesfollow/all-cancer-typesBladder Cancerfollow/category/bladderBreast Cancerfollow/category/breast-cancerChronic Lymphocytic Leukemia (CLL)follow/category/cllColorectal Cancerfollow/category/colorectal-cancerHepatocellular Carcinoma (HCC)follow/category/hccLung Cancerfollow/category/lung-cancerMultiple Myelomafollow/category/multiple-myelomaNon-Hodgkin"s Lymphoma (NHL)follow/category/nhlOvarian Cancerfollow/category/ovarian-cancerProstate Cancerfollow/category/prostate-cancerRenal Cell Carcinoma (RCC)follow/category/rccAll Cancer Typesfollow/all-cancer-typesConferencesfollow/category/conference-coverageASCO Annual Meeting Conference Coveragefollow/category/asco-annual-meeting-coverageASCO GI Conference Coveragefollow/category/asco-gi-conference-coverageASCO GU Conference Coveragefollow/category/asco-gu-conference-coverageASH Conference Coveragefollow/category/ash-conference-coverageCOA Conference Coveragefollow/category/coa-conference-coverageESMO Conference Coveragefollow/category/esmo-conference-coverageSABCS Conference Coveragefollow/category/sabcs-conference-coverageSNO Conference Coveragefollow/category/sno-conference-coverageAll Conference Coveragefollow/category/conference-coverageExpert Insightsfollow/category/expert-insightsCase Studiesfollow/case-study-archiveClinical Roundtablesfollow/clinical-roundtable-archiveJournal Scansfollow/journal-scan-archiveLeading Thoughtsfollow/leading-thoughts-archivePeer-Spectives Podcastfollow/podcasts/peer-spectivesVideo Centerfollow/video-centerBusiness & Policyfollow/category/business-and-policyOncology Businessfollow/category/oncology-businessPolicy and Valuefollow/category/policy-and-valueOBR Radarfollow/radarCOA Conference Coveragefollow/category/coa-conference-coverageACCC / CCBS Conference Coveragefollow/category/accc-ccbs-conference-coveragePrivacy Policyfollowhttps://www.remedyhealthmedia.com/privacy-policyTerms of Usefollowhttps://www.remedyhealthmedia.com/terms-useAdvertising Policyfollowhttps://assets.ctfassets.net/vj6m823j1lj3/6ElwM8SUKI8owwumaag4UM/5b3a118111bfe953126ef7678c49b246/Remedy_Advertising_Policy_6-26-18.pdfAdvertise With Usfollowhttps://www.remedyhealthmedia.com/content/advertise-usRemedy Health Media Sitesfollowhttps://www.remedyhealthmedia.com/brands-partnersDo Not Sell My Infofollowhttps://jupiter.obroncology.com/preferences/About Usfollow/aboutEditorial Boardfollow/editorial-boardContact Usfollowhttps://www.obroncology.com/about#contactTrainingfollow/trainingfollowhttps://twitter.com/obrtweetsfollowhttps://linkedin.com/company/oncology-business-reviewOvarian CancerOCT 28Evidence for Neoadjuvant Chemo in Ovarian CancerChristina BennettUpfront surgery is regarded as the default treatment for advanced ovarian cancer, but substantial evidence supports neoadjuvant chemotherapy for patients.follow/article/more-evidence-supports-neoadjuvant-chemo-for-advanced-ovarian-cancerBreast CancerOCT 22ESMO Breast Cancer HighlightsSara Hurvitz, MDSara Hurvitz, MD, of UCLA Jonsson, provides an overview of practice-changing breast cancer data from ESMO 2021.follow/video/breast-cancer-highlights-from-esmo-2021COVID-19OCT 20Therapies Could Reduce COVID-19 RisksAaron TallentAntibody combinations or antiviral drugs could prevent infection or lower risk of progression to severe COVID-19 for people with cancer.follow/article/investigational-therapies-could-reduce-covid-19-risks-for-cancer-patientsBusiness & PolicyOCT 8Prior Authorization and Drug Costs Impede CareKate O’RourkeStudies presented at the ASCO Quality Care Symposium showed the impacts of prior authorization requirements and out-of-pocket drug costs on patients.follow/article/prior-authorization-and-drug-costs-often-impede-care-studies-suggestOBR Daily: The Latest Oncology News Waiting in Your InboxSign Upfollowhttps://www.obroncology.com/newsletterDrug & Regulatory InformationOCT 29Immutep Receives Positive EMA Scientific Advice for Further Clinical Development of Efti in MBC Including Phase IIISource: Yahoo! Financefollow/news/immutep-receives-positive-ema-scientific-advice-for-further-clinicalBusiness & PolicyOCT 29BridgeBio Pharma Announces Collaborations with Columbia University and Mount Sinai to Develop Potential Therapies for Genetic Diseases and CancersSource: Yahoo! Financefollow/news/bridgebio-pharma-announces-collaborations-with-columbia-university-and-mountBusiness & PolicyOCT 29EU Orders Illumina To Keep Grail A Separate CompanySource: Reutersfollow/news/eu-orders-illumina-to-keep-grail-a-separate-companyBusiness & PolicyOCT 29Caris Precision Oncology Alliance Partners with the National Cancer Institute, Part of the National Institutes of Health, to Expand Collaborative Clinical Research EffortsSource: Markets Insiderfollow/news/caris-precision-oncology-alliance-partners-with-the-national-cancerMore Newsfollowhttps://www.obroncology.com/category/latest-oncology-headlinesHoward S. Hochster, MDfollow/contributor/howard-hochsterH. Jack West, MDfollow/contributor/jack-westTed Okonfollow/contributor/ted-okonThomas Marsland, MDfollow/contributor/thomas-marslandWilliam McGivney, PhDfollow/contributor/william-mcgivneyAll Commentaryfollowhttps://www.obroncology.com/category/editorial-board-commentaryPeer-Spectives PodcastSEP 23ARCHES Data in Prostate Cancer at ESMOAndrew Armstrong, MDfollow/podcast/esmo-21-the-arches-study-and-progress-in-metastatic-and-non-metastatic-hormone-sensitive-prostate-cancerPeer-Spectives PodcastJUL 22Ovarian Cancer Highlights from ASCO 2021Robert Coleman, MDfollow/podcasts/ovarian-cancer-clinical-highlights-from-asco-2021Peer-Spectives PodcastJUL 14Post-EHA Treatment Trends in Chronic Lymphocytic Leukemia (CLL)Peter Hillmen, MDfollow/podcasts/post-eha-2021-latest-treatment-trends-in-the-management-of-chronicMore Episodesfollowhttps://www.obroncology.com/podcasts/peer-spectivesLeading ThoughtsSEP 30I-O in NSCLC After Targeted Therapyfollow/leading-thoughts/is-there-a-role-for-immunotherapy-or-immunotherapy-combinations-in-non-small-cell-lung-cancer-patientsLeading ThoughtsSEP 27Emerging Data on NSCLC With Brain Metastasesfollow/leading-thoughts/emerging-data-on-chemo-immunotherapy-in-patients-with-advanced-non-small-cell-lung-cancer-and-brain-metastasesLeading ThoughtsAUG 17Optimal Radiation Therapy for Limited-Stage SCLCfollow/leading-thoughts/an-exploration-of-optimal-radiation-therapy-for-limited-stage-small-cell-lung-cancerMore Episodesfollowhttps://www.obroncology.com/leading-thoughts-archiveBusiness & PolicyOCT 29Pharma Leaders Discuss Out-of-Pocket Drug CostsAaron Tallentfollow/article/out-of-pocket-costs-should-be-focus-of-addressing-drug-prices-pharma-leaders-sayBusiness & PolicyOCT 29Pharma Leaders Discuss Out-of-Pocket Drug CostsAaron TallentAt the Community Oncology Alliance’s Payer Exchange Summit, pharma leaders discussed the relationship between list prices and out-of-pocket costs.follow/article/out-of-pocket-costs-should-be-focus-of-addressing-drug-prices-pharma-leaders-sayBusiness & PolicyOCT 29Oncologists Work to Check PBMs at State LevelAaron Tallentfollow/article/oncologists-work-to-check-pbms-at-the-state-levelBusiness & PolicyOCT 29Oncologists Work to Check PBMs at State LevelAaron TallentRecently passed legislation in three states aims to limit the power of pharmacy benefit managers.follow/article/oncologists-work-to-check-pbms-at-the-state-levelClinical RoundtablesOCT 28PARPs Have Changed Ovarian Cancer TreatmentRobert Coleman, MDfollow/clinical-roundtable/how-PARPs-have-changed-the-ovarian-cancer-clinical-landscapeClinical RoundtablesOCT 28PARPs Have Changed Ovarian Cancer TreatmentRobert Coleman, MDThree leading ovarian cancer experts discuss how PARP inhibitors have evolved and transformed the ovarian cancer clinical landscape at a recent roundtable.follow/clinical-roundtable/how-PARPs-have-changed-the-ovarian-cancer-clinical-landscapeOvarian CancerOCT 28Evidence for Neoadjuvant Chemo in Ovarian CancerChristina Bennettfollow/article/more-evidence-supports-neoadjuvant-chemo-for-advanced-ovarian-cancerOvarian CancerOCT 28Evidence for Neoadjuvant Chemo in Ovarian CancerChristina BennettUpfront surgery is regarded as the default treatment for advanced ovarian cancer, but substantial evidence supports neoadjuvant chemotherapy for patients.follow/article/more-evidence-supports-neoadjuvant-chemo-for-advanced-ovarian-cancerBreast CancerOCT 22ESMO Breast Cancer HighlightsSara Hurvitz, MDfollow/video/breast-cancer-highlights-from-esmo-2021Breast CancerOCT 22ESMO Breast Cancer HighlightsSara Hurvitz, MDSara Hurvitz, MD, of UCLA Jonsson, provides an overview of practice-changing breast cancer data from ESMO 2021.follow/video/breast-cancer-highlights-from-esmo-2021COVID-19OCT 20Therapies Could Reduce COVID-19 RisksAaron Tallentfollow/article/investigational-therapies-could-reduce-covid-19-risks-for-cancer-patientsCOVID-19OCT 20Therapies Could Reduce COVID-19 RisksAaron TallentAntibody combinations or antiviral drugs could prevent infection or lower risk of progression to severe COVID-19 for people with cancer.follow/article/investigational-therapies-could-reduce-covid-19-risks-for-cancer-patientsGastrointestinal CancerOCT 20Treatment of Lesions Reduces Anal Cancer RiskMarcus A. Banksfollow/article/removing-precancerous-lesions-reduces-anal-cancer-risk-in-people-with-hivGastrointestinal CancerOCT 20Treatment of Lesions Reduces Anal Cancer RiskMarcus A. BanksFor people with HIV, removing precancerous anal lesions can reduce incidence of anal cancer, the ANCHOR study found.follow/article/removing-precancerous-lesions-reduces-anal-cancer-risk-in-people-with-hivBusiness & PolicyOCT 8Prior Authorization and Drug Costs Impede CareKate O’Rourkefollow/article/prior-authorization-and-drug-costs-often-impede-care-studies-suggestBusiness & PolicyOCT 8Prior Authorization and Drug Costs Impede CareKate O’RourkeStudies presented at the ASCO Quality Care Symposium showed the impacts of prior authorization requirements and out-of-pocket drug costs on patients.follow/article/prior-authorization-and-drug-costs-often-impede-care-studies-suggestLeading ThoughtsSEP 30I-O in NSCLC After Targeted Therapyfollow/leading-thoughts/is-there-a-role-for-immunotherapy-or-immunotherapy-combinations-in-non-small-cell-lung-cancer-patientsLeading ThoughtsSEP 30I-O in NSCLC After Targeted TherapyThree lung cancer experts discuss the role of immunotherapy or chemo-immunotherapy after targeted therapy is exhausted in NSCLC patients with driver mutations.follow/leading-thoughts/is-there-a-role-for-immunotherapy-or-immunotherapy-combinations-in-non-small-cell-lung-cancer-patientsBusiness & PolicySEP 29Oncologists Adjust to the Open Notes EraAaron Tallentfollow/article/oncologists-adjust-to-the-open-notes-eraBusiness & PolicySEP 29Oncologists Adjust to the Open Notes EraAaron TallentThe 21st Century Cures Act mandated that electronic medical records be made available to patients without delay.follow/article/oncologists-adjust-to-the-open-notes-eraPrivacy Policyfollowhttps://www.remedyhealthmedia.com/privacy-policyTerms of Usefollowhttps://www.remedyhealthmedia.com/terms-useAdvertising Policyfollowhttps://assets.ctfassets.net/vj6m823j1lj3/6ElwM8SUKI8owwumaag4UM/5b3a118111bfe953126ef7678c49b246/Remedy_Advertising_Policy_6-26-18.pdfAdvertise With Usfollowhttps://www.remedyhealthmedia.com/content/advertise-usRemedy Health Media Sitesfollowhttps://www.remedyhealthmedia.com/brands-partnersDo Not Sell My Infofollowhttps://jupiter.obroncology.com/preferences/About Usfollow/aboutEditorial Boardfollow/editorial-boardContact Usfollowhttps://www.obroncology.com/about#contactTrainingfollow/trainingfollowhttps://twitter.com/obrtweetsfollowhttps://linkedin.com/company/oncology-business-reviewStart Surveyfollow#/
- Social signals
- Title: 53 characters.
- Description: 153 characters.
- Domain Authority
- Monthly pages viewed: 4664
- Estimated worth: 2135 dollars
We have developed a useful service for retrieve WhoIs information. "Whois" is a term that begins from the early days of the Internet, based on Unix operating system and university networks. On the Unix console, the command "whois" tries to determine the identity of the domain's registrant.
It is a means for Internet users to query various types of information such as IP addresses, user data and also domain data.
✦ SEO Report
Title / Meta tags
OBR Oncology: a leading oncology digital media outlet
OBR provides high quality, thought-provoking information to oncology professionals with the goal of improving the outcomes and lives of cancer patients.
Image Analysis
A right example for an HTML image tag:
<img src="prettyimage.jpg" alt="image description" title="image tooltip"/>
For SEO performance, you must write an alternative text. The alternative text must describe the image's content. Also, the alt tag is used for blind people. Their browsers tell them all about the description of the image.
Heading
Content Analysis
Code Analysis
We have not found hyphens (-) or underscores (_) in your URL. Google and expert domainers do not recommend buying domains with hyphens or underscores.
When a visitor came to your website you can not fail. The user wants your page to load in a second. You know that it is difficult sometimes to display content in the first second but if the user has to wait too much time you can lose that user. If your page is too slow, you will lose a lot of web traffic. Your project URL load time is ms, it is class speed. This speed not fine and need to be improved. It is over the average. Our Speed analyzer has shown that www.obroncology.com is as follows:
A huge portion of visitors to your website are usually in rush and nobody is fond of waiting too much before your website loads its content. If your website is slow, you will lose a lot of visitors. Your homepage load time is ms is class speed. This speed not fine and need to be improved. It is over the average. Our Speed analyzer has shown that www.obroncology.com is as follows:
Speed:
Page Load Time: ms
rhm, global-header-wrap, ad-wrapper, rhm--ad, GlobalHeader_content__2LzER, GlobalHeader_container__JClHi, GlobalHeader_link__2Y2ZV newsletter body-label-heavy, global-header, container GlobalHeader_coloredHeaderContainer__26fkb, brand-logo, GlobalHeader_icon__3cehm, GlobalHeader_hamburger__10FaA GlobalHeader_mobile__zLki9, modal-overlay hidden, modal-body, nav-search-form NavSearchForm_nav-search-form__2CvyZ, form-wrap, input-wrap static-label search-wrap, clear-search, remedy-icon, btn btn search-btn, util-show-after-tablet-portrait, util-hide-after-tablet-portrait, nav-links, nav-noncontext listbox-wrapper, listbox Listbox_listbox__LQlzF, listbox-item-active, , global-footer, footer-top, container, footer-wrapper, newsletter-form NewsletterForm_newsletter-form__1hbGR, input-wrap static-label, btn btn-secondary, footer-follow, footer-social, social-buttons SocialButtons_social-buttons__23FEc, footer-copyright, main-wrap, template-homepage, container-rr container, promosWrapper FeaturedEntries_featuredEntries__2fzji featured-entries FeaturedEntries_featuredEntriesBlock__2W5JY, FeaturedEntries_promosWrapper__Mmm5D, FeaturedEntries_promoRow__1s5_c, promoWrapper CardHorizontalLarge_cardHorizontalLarge__3iytf Card_Card__3kXfc, promos-center, image-wrap promo-image, overline, overline-main body-label-small-heavy promoLabel, overline-date body-label-small, undefined display-header-3 promoHeading, promoByline CardHorizontalLarge_promoAuthor__1ehRL display-small, body-small promo-description promoDescription, image-wrap promo-video headshot, embed-block, promoWrapper marketingPromo, display-header-3 promoHeading, promoButton btn btn-secondary btn-standard button-standard, content, promosWrapper inserted-ad, util-show-after-tablet-portrait util-hide-after-desktop ad-wrapper, util-hide-after-tablet-portrait ad-wrapper, promosWrapper, SectionTitle_SectionTitle__17lom, display-header-6, promoWrapper CardHorizontalSmall_CardHorizontalSmall__UTqZA Card_Card__3kXfc, display-header-5 promoHeading, promoByline display-small, promosButton btn btn btn-large btn-alt, image-wrap promo-image headshot, promosWrapper Default_DefaultPromos__3atZQ promos-default, Default_grid__3waS_, promoWrapper CardHorizontalSmall_CardHorizontalSmall__UTqZA Default_promo__3C1Z0 Card_Card__3kXfc, image-wrap promo-microphone headshot, image-wrap promo-video, promosWrapper entries-list, EntriesList_grid__1vIuG, EntriesList_mobile__kWzTh, EntriesList_desktop__7kKsg, promoWrapper CardHorizontalMedium_CardHorizontalMedium__1hBnY Card_Card__3kXfc, display-header-4 promoHeading, promo-description body-small promoDescription, EntriesList_desktop__7kKsg EntriesList_noBorder__E2-IS, btn btn-large btn-alt, survey_survey__2Gq8k survey-slide-out, survey_surveyClose__3ng72, survey_surveyCta__1bIRb survey-cta, survey_surveyHeadline__K0vOI survey-headline, survey_surveyBody__1V2VN survey-body, survey_surveyBtn__2Wpbh survey-button,
How much money does obroncology.com earn?
The domain obroncology.com has a revenue of $16.324 monthly. We have calculated this earning based on the daily traffic of this domain.
Has obroncology.com Google Analytics code?
The domain obroncology.com has not the Google Analytics code inside its HTML.
Has obroncology.com Google Adsense code?
The domain obroncology.com has not the Google Adsense code inside its HTML.
What IP obroncology.com has?
The domain obroncology.com has IP 18.66.196.2.
Which charset obroncology.com has?
An IP address is a string of numbers used to make devices accessible for communication.
The domain obroncology.com has the charset UTF-8.
How many internal links obroncology.com has?
To display an HTML page correctly, a web browser must know which character set to use.
The charset change for every language set of characters like English, Chinese or Russian.
The domain obroncology.com has 0 links.
How many words obroncology.com has?
The links are an important part of the web.
The links help us to navigate between pages.
The domain obroncology.com has 826 words.
The number of words is a crucial metric of the website.
The websites need a large quantity of text to explain the content of the site
Last visited